References
- Chilet-Rosell, E. (2014). Gender bias in clinical research, pharmaceutical marketing, and the prescription of drugs. Global Health Action, 7, 25484. https://doi.org/10.3402/gha.v7.25484
- Cohen, D. (2017). Cancer drugs: High price, uncertain value. BMJ (Clinical Research ed.), 359, j4543. https://doi.org/10.1136/bmj.j4543
- Davis, C., Lexchin, J., Jefferson, T., Gøtzsche, P., & McKee, M. (2016). "Adaptive pathways" to drug authorisation: Adapting to industry? BMJ (Clinical Research ed.), 354, i4437. https://doi.org/10.1136/bmj.i4437
- Davis, C., Naci, H., Gurpinar, E., Poplavska, E., Pinto, A., & Aggarwal, A. (2017). Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: Retrospective cohort study of drug approvals 2009-13. BMJ (Clinical Research ed.), 359, j4530. https://doi.org/10.1136/bmj.j4530
- Duma, N., Vera Aguilera, J., Paludo, J., Haddox, C. L., Gonzalez Velez, M., Wang, Y., Leventakos, K., Hubbard, J. M., Mansfield, A. S., Go, R. S., & Adjei, A. A. (2018). Representation of minorities and women in oncology clinical trials: Review of the past 14 years. Journal of Oncology Practice, 14(1), e1–e10. https://doi.org/10.1200/JOP.2017.025288
- EMA. (2018). Annual report on the use of the special contribution for orphan medicinal products. https://www.ema.europa.eu/en/documents/report/annual-report-use-specialcontribution-orphan-medicinal-products-2018_en.pdf
- Ermisch, M., Bucsics, A., Vella Bonanno, P., Arickx, F., Bybau, A., Bochenek, T., van de Casteele, M., Diogene, E., Fürst, J., Garuolienė, K., van der Graaff, M., Gulbinovič, J., Haycox, A., Jones, J., Joppi, R., Laius, O., Langner, I., Martin, A. P., Markovic-Pekovic, V., … Godman, B. (2016). Payers’ views of the changes arising through the possible adoption of adaptive pathways. Frontiers in Pharmacology, 7, 305. https://doi.org/10.3389/fphar.2016.00305
- ESMO. (2017). Ovarian Cancer: An ESMO Guide for Patients. https://www.esmo.org/content/download/10097/201883/file/EN-Ovarian-Cancer-Guide-for-Patients.pdf
- European Commission. (2018). Eurostat [Data base online]. https://ec.europa.eu/eurostat/data/database
- European Medicines Agency. (2018). Clinical trial register [Data base online]. https://www.clinicaltrialsregister.eu/ctr-search/search
- Ferlay, J., Colombet, M., Soerjomataram, I., Dyba, T., Randi, G., Bettio, M., Gavin, A., Visser, O., & Bray, F. (2018). Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. European Journal of Cancer, 103, 356–387. https://doi.org/10.1016/j.ejca.2018.07.005
- Franco, P. (2013). Orphan drugs: The regulatory environment. Drug Discovery Today, 18(3–4), 163–172. https://doi.org/10.1016/j.drudis.2012.08.009
- Gaeta, M., Campanella, F., Capasso, L., Schifino, G. M., Gentile, L., Banfi, G., Pelissero, G., & Ricci, C. (2017). An overview of different health indicators used in the European Health Systems. Journal of Preventive Medicine and Hygiene, 58(2), E114–E120.
- Gammie, T., Lu, C. Y., & Babar, Z. U. (2015). Access to orphan drugs: A comprehensive review of legislations, regulations and policies in 35 countries. PLoS One, 10(10), e0140002. https://doi.org/10.1371/journal.pone.0140002
- González, P., Macho-Stadler, I., & Pérez-Castrillo, D. (2016). Private versus social incentives for pharmaceutical innovation. Journal of Health Economics, 50, 286–297. https://doi.org/10.1016/j.jhealeco.2015.12.003
- Heemstra, H. E., de Vrueh, R. L., van Weely, S., Büller, H. A., & Leufkens, H. G. (2008). Orphan drug development across Europe: Bottlenecks and opportunities. Drug Discovery Today, 13(15–16), 670–676. https://doi.org/10.1016/j.drudis.2008.05.001
- Husereau, D., Henshall, C., & Jivraj, J. (2014). Adaptive approaches to licensing, health technology assessment, and introduction of drugs and devices. International Journal of Technology Assessment in Health Care, 30(3), 241–249. https://doi.org/10.1017/S0266462314000191
- Joppi, R., Bertele’, V., & Garattini, S. (2013). Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU. European Journal of Clinical Pharmacology, 69(4), 1009–1024. https://doi.org/10.1007/s00228-012-1423-2
- Kaufmann, P., Pariser, A.R., Austin, C. (2018). From scientific discovery to treatments for rare diseases – the view from the National Center for Advancing Translational Sciences – Office of Rare Diseases Research. Orphanet Journal of Rare Diseases, 13(1), 196. https://doi.org/10.1186/s13023-018-0936-x
- Martinalbo, J., Bowen, D., Camarero, J., Chapelin, M., Démolis, P., Foggi, P., Jonsson, B., Llinares, J., Moreau, A., O’Connor, D., Oliveira, J., Vamvakas, S., & Pignatti, F. (2016). Early market access of cancer drugs in the EU. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 27(1), 96–105. https://doi.org/10.1093/annonc/mdv506
- Matesanz, R., Domínguez-Gil, B., Coll, E., Mahíllo, B., & Marazuela, R. (2017). How Spain reached 40 deceased organ donors per million population. American Journal of Transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 17(6), 1447–1454. https://doi.org/10.1111/ajt.14104
- Moliner, A. M., & Waligora, J. (2017). The European Union Policy in the Field of Rare Diseases. Advances in Experimental Medicine and Biology, 1031, 561–587. https://doi.org/10.1007/978-3-319-67144-4_30
- Mullard, A. (2012). 2011 FDA drug approvals. Nature Reviews. Drug Discovery, 11(2), 91–94. https://doi.org/10.1038/nrd3657
- Pauwels, K., Huys, I., Casteels, M., De Nys, K., & Simoens, S. (2014). Market access of cancer drugs in European countries: Improving resource allocation. Targeted Oncology, 9(2), 95–110. https://doi.org/10.1007/s11523-013-0301-x
- Pinxten, W., Denier, Y., Dooms, M., Cassiman, J. J., & Dierickx, K. (2012). A fair share for the orphans: Ethical guidelines for a fair distribution of resources within the bounds of the 10-year-old European Orphan Drug Regulation. Journal of Medical Ethics, 38(3), 148–153. https://doi.org/10.1136/medethics-2011-100094
- Prasad, V. (2017). Do cancer drugs improve survival or quality of life?BMJ (Clinical Research ed.), 359, j4528. https://doi.org/10.1136/bmj.j4528
- Rollet, P., Lemoine, A., & Dunoyer, M. (2013). Sustainable rare diseases business and drug access: No time for misconceptions. Orphanet Journal of Rare Diseases, 8, 109. https://doi.org/10.1186/1750-1172-8-109
- Romaniuk, P., & Szromek, A. R. (2016). The evolution of the health system outcomes in Central and Eastern Europe and their association with social, economic and political factors: An analysis of 25 years of transition. BMC Health Services Research, 16, 95. https://doi.org/10.1186/s12913-016-1344-3
- Weale, A. (2015). Reflecting on ‘Are health problems systemic? Politics of access and choice under Beveridge and Bismarck systems’. Health Economics, Policy and Law, 10(4), 431–435. https://doi.org/10.1017/S1744133115000171